133 related articles for article (PubMed ID: 22726925)
1. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
Sunose M; Bell K; Ellard K; Bergamini G; Neubauer G; Werner T; Ramsden N
Bioorg Med Chem Lett; 2012 Jul; 22(14):4613-8. PubMed ID: 22726925
[TBL] [Abstract][Full Text] [Related]
2. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
[TBL] [Abstract][Full Text] [Related]
3. SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors.
Bell K; Sunose M; Ellard K; Cansfield A; Taylor J; Miller W; Ramsden N; Bergamini G; Neubauer G
Bioorg Med Chem Lett; 2012 Aug; 22(16):5257-63. PubMed ID: 22819766
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.
Oka Y; Yabuuchi T; Oi T; Kuroda S; Fujii Y; Ohtake H; Inoue T; Wakahara S; Kimura K; Fujita K; Endo M; Taguchi K; Sekiguchi Y
Bioorg Med Chem; 2013 Dec; 21(24):7578-83. PubMed ID: 24262886
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
[TBL] [Abstract][Full Text] [Related]
6. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation.
Ellard K; Sunose M; Bell K; Ramsden N; Bergamini G; Neubauer G
Bioorg Med Chem Lett; 2012 Jul; 22(14):4546-9. PubMed ID: 22738635
[TBL] [Abstract][Full Text] [Related]
8. Modification of N-(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)acetamide as PI3Ks inhibitor by replacement of the acetamide group with alkylurea.
Wang XM; Mao S; Cao L; Xie XX; Xin MH; Lian JF; Cao YX; Zhang SQ
Bioorg Med Chem; 2015 Sep; 23(17):5662-71. PubMed ID: 26210161
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
10. Identification of the first potent, selective and bioavailable PPARα antagonist.
Bravo Y; Baccei CS; Broadhead A; Bundey R; Chen A; Clark R; Correa L; Jacintho JD; Lorrain DS; Messmer D; Stebbins K; Prasit P; Stock N
Bioorg Med Chem Lett; 2014 May; 24(10):2267-72. PubMed ID: 24745969
[TBL] [Abstract][Full Text] [Related]
11. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S
Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.
Zhao H; Serby MD; Xin Z; Szczepankiewicz BG; Liu M; Kosogof C; Liu B; Nelson LT; Johnson EF; Wang S; Pederson T; Gum RJ; Clampit JE; Haasch DL; Abad-Zapatero C; Fry EH; Rondinone C; Trevillyan JM; Sham HL; Liu G
J Med Chem; 2006 Jul; 49(15):4455-8. PubMed ID: 16854050
[TBL] [Abstract][Full Text] [Related]
13. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
Pomel V; Klicic J; Covini D; Church DD; Shaw JP; Roulin K; Burgat-Charvillon F; Valognes D; Camps M; Chabert C; Gillieron C; Françon B; Perrin D; Leroy D; Gretener D; Nichols A; Vitte PA; Carboni S; Rommel C; Schwarz MK; Rückle T
J Med Chem; 2006 Jun; 49(13):3857-71. PubMed ID: 16789742
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
[TBL] [Abstract][Full Text] [Related]
16. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
18. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
19. 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
Tehrani LR; Smith ND; Huang D; Poon SF; Roppe JR; Seiders TJ; Chapman DF; Chung J; Cramer M; Cosford ND
Bioorg Med Chem Lett; 2005 Nov; 15(22):5061-4. PubMed ID: 16183275
[TBL] [Abstract][Full Text] [Related]
20. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
Nishimura N; Siegmund A; Liu L; Yang K; Bryan MC; Andrews KL; Bo Y; Booker SK; Caenepeel S; Freeman D; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Whittington DA; Zalameda L; Zhang N; Hughes PE; Norman MH
J Med Chem; 2011 Jul; 54(13):4735-51. PubMed ID: 21612232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
